LON:TRX Tissue Regenix Group (TRX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Tissue Regenix Group Stock (LON:TRX) Get Tissue Regenix Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range 0.07▼ 0.0752-Week Range N/AVolumeN/AAverage Volume169,613 shsMarket Capitalization£52 thousandP/E RatioN/ADividend Yield4.12%Price TargetN/AConsensus RatingN/A Company Overview Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures. Read More Receive TRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRX Stock News HeadlinesTissue Regenix Group PLCApril 22, 2026 | marketwatch.comCellRight Tech: Private Equity Funding SecuredJanuary 8, 2026 | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 20 at 1:00 AM | Profits Run (Ad)CellRight Technologies, LLC Announces Update and Senior Leadership ChangesOctober 21, 2025 | finance.yahoo.comTissue Regenix Group PLC (LSE:TRX) Full Year 2024 Earnings Call Highlights: Record Profit and ...July 3, 2025 | finance.yahoo.comTissue Regenix Scraps Sale Plans, Flags Profit AheadApril 8, 2025 | marketwatch.comTissue Regenix Group Regulatory NewsFebruary 18, 2025 | lse.co.ukTissue Regenix Group Share Chat (TRX)November 3, 2024 | lse.co.ukSee More Headlines TRX Stock Analysis - Frequently Asked Questions How were Tissue Regenix Group's earnings last quarter? Tissue Regenix Group plc (LON:TRX) issued its earnings results on Wednesday, September, 2nd. The company reported ($0.16) EPS for the quarter. Tissue Regenix Group had a negative net margin of 6.77% and a negative trailing twelve-month return on equity of 3.16%. How do I buy shares of Tissue Regenix Group? Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Tissue Regenix Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank (SWDBY), Trevena (TRVN) and Barrick Gold (ABX). Company Calendar Last Earnings9/02/2020Today6/20/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPrecious Metals Current SymbolLON:TRX CIKN/A Webwww.tissueregenix.com Phone+44-1904-567609FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.11 million Net Margins-6.77% Pretax MarginN/A Return on Equity-3.16% Return on Assets0.50% Debt Debt-to-Equity Ratio37.46 Current Ratio2.88 Quick Ratio2.36 Sales & Book Value Annual Sales£27.75 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.70 Book ValueGBX 41.58 per share Price / BookN/AMiscellaneous Outstanding Shares71,235,000Free FloatN/AMarket Cap£52 thousand OptionableNot Optionable Beta1.61 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (LON:TRX) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tissue Regenix Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tissue Regenix Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
